Learning Objectives

Saturday - November 5, 2011

Philadelphia, PA

Learning Objectives
After completing this activity the participant should be better able to:

• Select lung cancer patients for personalized chemotherapy based on histology along with predictive and prognostic markers
• Identify the role of personalized maintenance therapy in the lung cancer
• Educate patients on the personalized and optimized multimodality therapy in the treatment of localized and advance lung cancer
• Summarize the importance of adjuvant and neoadjuvant therapy in early stage lung cancer
• Identify the role of histology in patient selection for integration of bevacizumab in the management of lung cancer
• Outline the clinical data supporting the optimal use of EGFR TKI's in the treatment of lung cancer based on biomarkers leading to change in practice
• Summarize the importance of managing primary and secondary resistance to anti-EGFR therapy in patients with lung cancer
• Describe novel therapeutic agents such as c-met inhibitors, HDAC inhibitors/ talactoferrin/STA 9090 and other HSP 90, ARQ197, EGFL-7, linifanib, farletuzumab/Hedge-Hog inhibitors that potentially improve upon standard chemotherapy
• Analyze the importance of novel treatment strategies for small cell lung cancer
• Educate patients on symptom control and management of toxicities associated with chemotherapy and targeted agents
• Utilize appropriate supportive cancer care in the era of targeted therapy